Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05647512

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Relapsed or Refractory Multiple Myeloma Clinical Trial

Official title:
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Clinical Trial Summary

A Phase I/II Study of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical Trial Description

A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-305 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05647512
Study type Interventional
Source LaNova Medicines Limited
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date January 18, 2023
Completion date December 30, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03837509 - INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05519085 - A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 3
Active, not recruiting NCT02099539 - QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00545519 - A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma Phase 1
Recruiting NCT05052970 - Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM Phase 1
Completed NCT03464916 - Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Phase 1
Recruiting NCT05455320 - A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment Phase 3
Withdrawn NCT05408026 - Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Phase 1/Phase 2
Active, not recruiting NCT04684108 - SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies Phase 1
Recruiting NCT05652335 - A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis Phase 1
Completed NCT03859427 - A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 3
Completed NCT01866293 - Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma Phase 1/Phase 2
Recruiting NCT06375044 - Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT01058434 - Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation Phase 2
Recruiting NCT04735575 - A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma Phase 1/Phase 2
Not yet recruiting NCT06298266 - To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma Early Phase 1
Recruiting NCT05572515 - A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Phase 3
Active, not recruiting NCT04798586 - MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma Phase 1
Terminated NCT02075021 - Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00478777 - A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Phase 3